LLY vs GILD
By Alex · Tickerpine
Eli Lilly and Company vs Gilead Sciences, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | GILD |
|---|---|---|
| Price | $1,208.12 | $127.88 |
| Market cap | $1.08T | $158.77B |
| P/E ratio | 42.9 | 17.4 |
| ROE | 107.46% | 43.36% |
| Profit margin | 34.99% | 30.99% |
| Revenue growth | 55.50% | 4.40% |
| Dividend yield | 0.57% | 2.56% |
| Beta | 0.52 | 0.33 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs GILD in plain English
- LLY is the bigger company — about 6.8× the market cap of GILD.
- GILD is cheaper on earnings (P/E 17.4 vs 42.9).
- LLY earns a higher return on equity (107% vs 43%).
- LLY is growing revenue faster (56% vs 4%).
- GILD has the higher dividend yield (2.56% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
GILD return calculator
See what $1,000 in Gilead Sciences, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.